Mobile

Phase 3, randomized, open-label study of the efficacy and safety of crizotinib versus pemetrexed/cisplatin or pemetrexed/carboplatin in previously untreated patients with non-squamous carcinoma of the...

Update Il y a 5 ans
Reference: EUCTR2010-021336-33

Phase 3, randomized, open-label study of the efficacy and safety of crizotinib versus pemetrexed/cisplatin or pemetrexed/carboplatin in previously untreated patients with non-squamous carcinoma of the lung harboring a translocation or inversion event involving the anaplastic lymphoma kinase (ALK) gene locus

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To demonstrate that crizotinib (Arm A) is superior to first-line chemotherapy (pemetrexed/cisplatin or pemetrexed/carboplatin) (Arm B), in prolonging PFS in patients with advanced nonsquamous NSCLC whose tumors harbor a translocation or inversion event involving the ALK gene locus.

Inclusion criteria

  • Non small cell lung cancer (NSCLC)

Links